Fungi usually infect the skin and mucosa. Healthy individuals can efficiently control such infections; however, in immunocompromised individuals and nosocomial patients, fungal infections may become systemic, at which point they are associated with significant morbidity. Candidiasis is the most common fungal infection, and is associated with prolonged hospital stays and high mortality rates. The premise underlying the proposed experiments is that understanding the mechanisms of activation of the inflammatory process that controls fungal infections in healthy individuals will reveal novel therapeutic target that can be used to treat candidiasis in susceptible patients. Here, we seek to uncover how activation of Nuclear Factor of Activated T cells (NFAT) in innate immune and non-immune cells induces protective immune responses against Candida, thus preventing invasive spread of the fungus and lethal systemic candidiasis. Inflammation is a protective vascular response to noxious stimuli that causes increased blood vessel permeability and recruitment of immune cells to the site of infection to combat the invading microorganism. Innate immune and tissue-specific non-immune cells regulate the development and potency of the inflammatory process via transcriptional and non-transcriptional responses, and lead to the formation of a protective adaptive immune memory. The NFAT family of transcription factors was originally associated with activation of adaptive immune cells; but we and others have demonstrated that the NFAT pathway is also potently activated in innate immune and non-immune cells following exposure to inflammatory stimuli, especially in response to fungal recognition. A major effect of NFAT activation is to induce a large increase in the production of prostaglandin (PG)E2 and interleukin (IL)-2, but the significance of the huge spike in the concentration of these molecules in response to fungi is totally unexplored.
We aim to test the hypothesis that, in response to fungal infection NFAT is activated in innate immune and non-immune cells to regulate the inflammatory process, destruction of the invading pathogen, and formation of a protective memory. We will use mouse models to determine how early NFAT activation orchestrates fungal recognition and destruction, efficient transport of pathogen to the draining lymph node (dLN), and remodeling of LN microarchitecture (important for adaptive immune cell activation and long lasting protection) during anti-fungal inflammatory responses. This represents a new, unexplored area of investigation, with important implications for gaining insights into the complexity of inflammation driven immunity, and for addressing the excess mortality and the length and financial burden of hospitalization, which present a potent mandate for designing improved means of preventing and treating candidiasis in adults and children. We contend that clarification of the role of NFAT activation during the initial phases of the inflammatory process will provide a fundamental breakthrough for designing new strategies for treating fungal infection, and will yield a greater understanding of the physiology of inflammation.

Public Health Relevance

Fungal infections have shown an abnormal increase in the last two decades and are the fourth most common cause of nosocomial bloodstream infections in the USA. In healthy people, fungal infections are efficiently controlled by the activation of a potent inflammatory response. Here, we hypothesize that innate immune and non-immune cells play crucial roles to support protective responses against fungal infections. We anticipate that these studies will be foundational for developing novel and effective therapeutic interventions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI121066-02
Application #
9232989
Study Section
Innate Immunity and Inflammation Study Section (III)
Program Officer
Love, Dona
Project Start
2016-03-01
Project End
2021-02-28
Budget Start
2017-03-01
Budget End
2018-02-28
Support Year
2
Fiscal Year
2017
Total Cost
$442,500
Indirect Cost
$192,500
Name
Boston Children's Hospital
Department
Type
Independent Hospitals
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Liu, Ning-Ning; Uppuluri, Priya; Broggi, Achille et al. (2018) Intersection of phosphate transport, oxidative stress and TOR signalling in Candida albicans virulence. PLoS Pathog 14:e1007076
Santus, William; Mingozzi, Francesca; Vai, Marina et al. (2018) Deep Dermal Injection As a Model of Candida albicans Skin Infection for Histological Analyses. J Vis Exp :
Radaelli, F; D'Alfonso, L; Collini, M et al. (2017) ?MAPPS: a novel phasor approach to second harmonic analysis for in vitro-in vivo investigation of collagen microstructure. Sci Rep 7:17468
Rusconi, Michela; Gerardi, Francesca; Santus, William et al. (2017) Inflammatory role of dendritic cells in Amyotrophic Lateral Sclerosis revealed by an analysis of patients' peripheral blood. Sci Rep 7:7853
Zanoni, Ivan; Granucci, Francesca; Broggi, Achille (2017) Interferon (IFN)-? Takes the Helm: Immunomodulatory Roles of Type III IFNs. Front Immunol 8:1661
Santus, William; Barresi, Simona; Mingozzi, Francesca et al. (2017) Skin infections are eliminated by cooperation of the fibrinolytic and innate immune systems. Sci Immunol 2:
Zanoni, Ivan; Tan, Yunhao; Di Gioia, Marco et al. (2017) By Capturing Inflammatory Lipids Released from Dying Cells, the Receptor CD14 Induces Inflammasome-Dependent Phagocyte Hyperactivation. Immunity 47:697-709.e3
Prosperi, Davide; Colombo, Miriam; Zanoni, Ivan et al. (2017) Drug nanocarriers to treat autoimmunity and chronic inflammatory diseases. Semin Immunol 34:61-67
Broggi, Achille; Tan, Yunhao; Granucci, Francesca et al. (2017) IFN-? suppresses intestinal inflammation by non-translational regulation of neutrophil function. Nat Immunol 18:1084-1093
Mingozzi, Francesca; Spreafico, Roberto; Gorletta, Tatiana et al. (2016) Prolonged contact with dendritic cells turns lymph node-resident NK cells into anti-tumor effectors. EMBO Mol Med 8:1039-51

Showing the most recent 10 out of 11 publications